Improving prognosis after surgery for gastric cancer
Mené en Asie sur 1 035 patients atteints d'un cancer gastrique de stade II ou III, cet essai multicentrique international de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité d'un traitement adjuvant combinant capécitabine et oxaliplatine après une gastrectomie D2 (durée médiane de suivi : 34 mois)
5-year overall survival is the gold standard measure to compare treatments for gastric cancer. However, it requires long follow-up, and might be affected by subsequent treatments or by death caused by unrelated diseases, especially in elderly people. Some studies have used other surrogates, such as progression-free survival, disease-free survival, or shorter endpoints, including two randomised trials from Asia of adjuvant treatment for gastric cancer...
The Lancet Oncology , commentaire, 2013